Editas Medicine Inc (EDIT)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $334.92M
Last updated: Nov 17, 2026 at 4:26 PM ET
Editas Medicine Inc (EDIT) Statistics
Editas Medicine (EDIT) has a market cap of $334.92M and an enterprise value of $298.57M. Revenue grew 417.26% over the last 12 months from the 12 months before. Its share count is up 70.50% from a year earlier.
Total Valuation
Enterprise value is 10.85% below the market cap, as cash exceeds debt.
| Market Cap | $334.92M |
|---|---|
| Enterprise Value | $298.57M |
| Latest price (Nov 17, 2026) | $1.82 |
Key Dates
The next earnings report is set for Mar 8, 2027, after the close.
| Next Earnings Date | Mar 8, 2027, after the close |
|---|---|
| Last Earnings Date | Nov 9, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 5.4x and 3.3x. Its year-end P/S ranged from 4.5x to 92.4x from 2016 to 2025.
| P/S Ratio | 5.4x |
|---|---|
| Forward P/S | 10.3x |
| P/B Ratio | 3.3x |
Price Statistics
The stock is down 29.81% over 52 weeks and trades 29.46% below its 50-day average.
| Beta (1Y) | 2.36 |
|---|---|
| 52-Week Change | -29.81% |
| 1-Month Change | -24.59% |
| 3-Month Change | -43.85% |
| 6-Month Change | -25.81% |
| 5-Year Change | -92.73% |
| 10-Year Change | -81.12% |
| Total Return (1Y) | -29.81% |
| Total Return (3Y CAGR) | -42.85% |
| Total Return (5Y CAGR) | -45.03% |
| Return vs SPY (1Y) | -41.90% |
| Max Drawdown (1Y) | -51.33% |
| Max Drawdown (3Y) | -91.18% |
| Sharpe Ratio (1Y) | -0.43 |
| Correlation with SPY (1Y) | 0.39 |
| 50-Day Average | $2.58 |
| 200-Day Average | $2.70 |
| 52-Week Range | $1.66 to $3.94 |
| RSI (14 Days) | 31.9 |
| Average Volume (20 Days) | 2.29M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 2.82x current liabilities, and total debt is 0.67x shareholder equity.
| Current Ratio | 2.82x |
|---|---|
| Quick Ratio | 2.82x |
| Debt / Equity | 0.67x |
| Interest Coverage | -27.52x |
Returns and Efficiency
Return on invested capital is -42.31% over the last 12 months, against a 5-year average of -97.11%.
| Return on Equity (ROE) | -85.45% |
|---|---|
| Return on Assets (ROA) | -32.92% |
| Return on Invested Capital (ROIC) | -42.31% |
| ROA (5Y Average) | -51.44% |
| ROIC (5Y Average) | -97.11% |
| Asset Turnover | 0.25x |
| Receivables Turnover | 9.88x |
Scores
EDIT has an Altman Z-Score of -9.76, in the distress zone below 1.81, and a Piotroski F-Score of 0 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -9.76 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 0 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue was $51.65M over the last 12 months.
| Revenue | $51.65M |
|---|---|
| Revenue Growth (YoY) | +417.26% |
| Gross Profit | $51.65M |
| Operating Income | -$75.59M |
| Pretax Income | -$72.22M |
| Net Income | -$72.22M |
| Reported EPS (TTM) | -$0.62 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 38.52% of the $219.41M in total assets.
| Cash and Equivalents | $93.17M |
|---|---|
| Total Debt | $56.82M |
| Net Cash | $36.35M |
| Net Cash Per Share | $0.24 |
| Working Capital | $130.39M |
| Shareholder Equity | $84.52M |
| Book Value Per Share | $0.55 |
| Total Assets | $219.41M |
| Total Liabilities | $134.89M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$110.21M |
|---|---|
| FCF Per Share | -$0.72 |
| Depreciation and Amortization | $2.53M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -146.35%.
| Gross Margin | 100.00% |
|---|---|
| Operating Margin | -146.35% |
| Pretax Margin | -139.82% |
| Net Margin | -139.82% |
Growth
Revenue grew 27.15% a year over 3 years.
| Revenue Growth (3Y CAGR) | +27.15% |
|---|---|
| Revenue Growth (5Y CAGR) | -14.89% |
| Book Value Per Share Growth (2Y CAGR) | -73.17% |
| Tangible Book Per Share Growth (2Y CAGR) | -73.17% |
Dividends and Yields
EDIT does not pay a dividend.
| Buyback Yield | -47.86% |
|---|---|
| Shareholder Yield | -47.86% |
Peer Position
Against 9 similar companies, EDIT has the 5th highest P/S.
P/S RatioPeer median 4.3x
ROICPeer median -23.38%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -14.43%
| P/S Ratio | 5.4x vs 4.3x median |
|---|---|
| ROIC | -42.31% vs -23.38% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +417.26% vs -14.43% median |
Analyst Forecast
Consensus estimates put revenue growth at -28.60% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | -28.60% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About EDIT
What is EDIT's market cap?
Editas Medicine has a market cap of $334.92M. Its enterprise value, which adds debt and subtracts cash, is $298.57M.
How many shares of EDIT are outstanding?
Editas Medicine has 153.60M shares outstanding. The count is up 70.50% from a year earlier.
Does EDIT pay a dividend?
No. Editas Medicine does not pay a dividend.
How much debt does EDIT have?
Editas Medicine has $56.82M of total debt and $93.17M of cash and equivalents, a net cash position of $36.35M.
EDIT pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors